Forkhead box P3 (FOXP3) has been found to be
overexpressed by a range of cancer cells and correlated with prognosis of
tumors. This finding raises the possibility that the development of anti-FOXP3
antibody test may be useful for clinical application. The present work was
designed to test whether circulating autoantibody to FOXP3 was altered in lung
cancer. 271 patients with non-small cell lung cancer (NSCLC) and 227 in control
subjects matched in age, gender and smoking history were recruited. Circulating
antiFOXP3 IgG antibody was tested using an inhouse enzymelinked immunosorbent
assay.
Student’s t-test showed that the levels of
IgG autoantibody to FOXP3 were significantly higher in patients with NSCLC than
control subjects (t = 7.67, P < 0.0001). Receiver operating characteristic
(ROC) analysis showed that the area under the ROC curve (AUC) was 0.70 (95% CI
0.65 - 0.75, SE ± 0.024), in which patients at stage 2 had the highest AUC of
0.75 (95%CI 0.67 - 0.81, SE ± 0.037), with a sensitivity of 31.4% against a
specificity of 90.3%. Analysis of quality control samples gave an inter-assay
deviation of 13.3% among 45 plates tested. Conclusions: Circulating IgG
autoantibody to FOXP3 may be a potential biomarker for lung cancer. The conclusions
is circulating IgG autoantibody to FOXP3 may be a potential biomarker for lung
cancer.
Article by Weili Wang,et al,from China.
Full access: http://mrw.so/3AIBo6
 |
| Image by Lisa Marie Cannon,from Flickr-cc. |
评论
发表评论